Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

January 5, 2025 DMDWarrioR

The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2025.

Read More Research

Next Generation Exon Skipping Therapies Developed for the Treatment of DMD

January 16, 2025 DMDWarrioR

Next generation exon skipping therapies for Duchenne Muscular Dystrophy (DMD) represent a promising area of research aimed at addressing the underlying genetic mutations that cause the disease.

Read More Research

We Call on Health Ministries and Pharmaceutical Manufacturers to Take Action on DMD

February 16, 2025 DMDWarrioR

We call on all health ministries around the world and manufacturers of DMD treatments approved by the FDA and EMA to take action.

Read More Editorials

Three Ongoing Clinical Trials of Elevidys Gene Therapy Temporarily Halted in Europe

April 1, 2025 DMDWarrioR

Following the death of a 16-year-old child receiving an Elevidys infusion, 3 ongoing clinical trials in Europe (Study 104, Study 302 and Study 303) were temporarily halted.

Read More Press Releases

DMD WarrioR’s Turkish Representative Shares His Views on Elevidys Gene Therapy

March 28, 2025 DMDWarrioR

We spoke to DMDWarrioR's Turkiye Representative about his perspective and concerns regarding Elevidys gene therapy. We also received surprising information about DMD studies in Turkiye.

Read More Editorials

Is Elevidys Cost Worthy? Clinical Trials Review of Elevidys Gene Therapy

March 2, 2025 DMDWarrioR

Is Elevidys Effective and Cost Worthy Compared to Clinical Trials?

Read More Editorials

Why Isn’t Roche Applying Marketing Authorization in Every Country for Elevidys Gene Therapy?

March 13, 2025 DMDWarrioR

If you are wondering when Elevidys gene therapy will come to your country, this article may help you get an idea.

Read More Editorials

What is Duchenne Muscular Dystrophy?

September 14, 2024 DMDWarrioR

Duchenne Muscular Dystrophy (DMD) is a genetic disorder that affects thousands of families worldwide. It primarily impacts boys, causing muscle degeneration and weakness over...

Read More DMD

Genetic Causes of Duchenne Muscular Dystrophy

October 4, 2024 DMDWarrioR

Duchenne muscular dystrophy (DMD) is rooted in the intricate world of genetics, specifically emanating from changes in a single gene known as the Dystrophin...

Read More DMD

Does My Child Have Duchenne Muscular Dystrophy (DMD)?

October 4, 2024 DMDWarrioR

When parents ponder the question, “Does My Child Have Duchenne Muscular Dystrophy (DMD)?” they often find themselves grappling with a whirlwind of emotions as...

Read More DMD
Is Elevidys Effective and Cost Worthy Compared to Clinical Trials? Roche Marketing Authorization Strategy in Every Country for Elevidys Gene Therapy. We spoke to DMDWarrioR's Turkiye Representative about his perspective and concerns regarding Elevidys gene therapy. We also received surprising information about DMD studies in Turkiye. Clinical Trials of Elevidys Gene Therapy Temporarily Halted in Europe by EMA

About our Mission

Many people in the world do not know what Duchenne muscular dystrophy is. Because only one in every 5,000 boys gets this disease. However, families and their surroundings whose children struggle with this disease have to live with the stress of this disease every day. We call them DMD Warriors.

DMDWarrior.com was established to raise awareness of this disease worldwide, facilitate access to treatments, and ensure that treatment costs are affordable.

dmd warrior dmdwarrior

What is our purpose?

One in every 5,000 children in the world is born with DMD, and many families only realize their child has the disease when they are 3-4 years old. FDA-approved treatments for DMD are too expensive for families to afford. Our goal is to reduce treatment costs and have the costs covered by the government.

Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

Home

Raising Awareness on Social Media

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

News & Articles

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

The European Commission (EC) has given conditional marketing authorization to the new histone deacetylase (HDAC) inhibitor Duvyzat (givinostat), Italfarmaco announced on 6th June. When...

New Positive Functional Data From The RGX-202 Affinity Duchenne® Trial Phase 1/2 Reported By Regenxbio

The Regenxbio press statement stated that the findings, which came from five patients in the AFFINITY DUCHENNE trial who were between the ages of...

PepGen Announces It Will Halt Clinical Trials of Exon 51 Skipping Study

PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in...

Entrada Therapeutics Receives EU Authorization to Start Exon 45 Skipping Clinical Trial in Duchenne Muscular Dystrophy

Entrada Therapeutics, today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial...

Entos Pharmaceuticals Develops Re-Dosable, Full-Length Dystrophin Gene Therapy: Fusogenix PLV Method

Entos Pharmaceuticals Inc. (Entos) is a biotech business that creates genetic therapies using its non-viral, redosable Fusogenix PLV delivery technology. CureDuchenne Ventures announced an...